The incidence of esophageal adenocarcinoma is rapidly increasing, with a 350% increase in its incidence since 1970 [1–3]. Currently, the number of new cases of esophageal cancer in the United States is estimated at 16,400 per year, with over half of these being esophageal adenocarcinoma [4]. Esophageal cancer is associated with a dismal overall 5-year survival of less than 15%; however, when detected early and confined to the esophagus, the 5-year survival can be as high as 85%, highlighting the need for early detection, thorough preoperative evaluation, and accurate clinical staging [4–6].